Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: A retrospective study

Journal of Thoracic Oncology

Volumn 10, Issue 3, 2015, Pages 492-499

  Lo Iacono, Marco ^a   Monica, Valentina ^a   Righi, Luisella ^a   Grosso, Federica ^b   Libener, Roberta ^b   Vatrano, Simona ^a   Bironzo, Paolo ^a   Novello, Silvia ^a   Musmeci, Loredana ^c   Volante, Marco ^a   Papotti, Mauro ^a   Scagliotti, Giorgio V ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b St Antonio Biagio Hospital   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

BAP1 gene; Genetic characterization; Genetic variation; Malignant pleural mesothelioma; Next generation sequencing; NF2 gene; PI3K gene

Indexed keywords

B RAF KINASE; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; PROTEIN KINASE LKB1; PROTEIN P53; VASCULOTROPIN RECEPTOR 2; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER STAGING; DISEASE COURSE; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; HRAS GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIT GENE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROFIBROMATOSIS TYPE 2 GENE; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PDGFRA GENE; PIK3CA GENE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STABILITY; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SMARCB1 GENE; TUMOR GENE; ENZYME IMMUNOASSAY; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; MESOTHELIOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; PLEURA TUMOR; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84938287128     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000436     Document Type: Article

References (32)

1. Grosso F, Scagliotti GV, Systemic treatment of malignant pleural mesothelioma. Future Oncol 2012 8 293 305
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003 21 2636 2644
3. Pass HI, Biomarkers and prognostic factors for mesothelioma. Ann Cardiothorac Surg 2012 1 449 456
4. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ, Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000 55 731 735
5. Travis W, Brambilla E, Muller-Hermelink H, Tumours of the Lung, Pleura, Thymus and Heart. Pathology and Genetics 2004 Lyon IARC Press
6. de Assis LV, Locatelli J, Isoldi MC, The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma. Biochim Biophys Acta 2014 1845 232 247
7. Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E, Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 2009 64 140 147
8. Bott M, Brevet M, Taylor BS, The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011 43 668 672
9. Testa JR, Cheung M, Pei J, Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011 43 1022 1025
10. Goldstein AM, Germline BAP1 mutations and tumor susceptibility. Nat Genet 2011 43 925 926
11. Cheung M, Talarchek J, Schindeler K, Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet 2013 206 206 210
12. AJCC TNM Cancer Staging 2010 Chicago Springer
13. Byrne MJ, Nowak AK, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004 15 257 260
14. Cappia S, Righi L, Mirabelli D, Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am J Clin Pathol 2008 130 58 64
15. Menges CW, Kadariya Y, Altomare D, Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. Cancer Res 2014 74 1261 1271
16. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M, The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003 33 357 365
17. Mechanic LE, Marrogi AJ, Welsh JA, Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis 2005 26 597 604
18. Han JY, Lee GK, Jang DH, Lee SY, Lee JS, Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008 113 799 807
19. Di Marzo D, Forte IM, Indovina P, Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle 2014 13 652 665
20. Kim JG, Sohn SK, Chae YS, TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol 2009 64 355 360
21. Yu H, Pak H, Hammond-Martel I, Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci U S A 2014 111 285 290
22. Reis RM, Martins A, Ribeiro SA, Molecular characterization of PDGFR-Alpha/PDGF-A and c-KIT/SCF in gliosarcomas. Cell Oncol 2005 27 319 326
23. Tamborini E, Miselli F, Negri T, Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res 2006 12 6920 6928
24. Wang AX, Chang JW, Li CY, Liu K, Lin YL, H-ras mutation detection in bladder cancer by COLD-PCR analysis and direct sequencing. Urol Int 2012 88 350 357
25. Cacciotti P, Barbone D, Porta C, SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res 2005 65 5256 5262
26. Kim KU, Wilson SM, Abayasiriwardana KS, A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 2005 33 541 548
27. Wallin JJ, Edgar KA, Guan J, GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 2011 10 2426 2436
28. Dolly SO, Krug LM, Wagner AJ, Evaluation of tolerability and anti-Tumor activity of GDC-0980, an oral PI3K/MTOR inhibitor, administered to patients with advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 2013 8 S307
29. Bianchi AB, Mitsunaga SI, Cheng JQ, High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 1995 92 10854 10858
30. Scoles DR, The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta 2008 1785 32 54
31. Riquelme E, Suraokar MB, Rodriguez J, Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma. J Thorac Oncol 2014 9 998 1007
32. Matullo G, Guarrera S, Betti M, Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study. PLoS One 2013 8 e61253